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Interleukin-1  (IL-1 ) and interleukin-1 receptor antagonist (IL-1RN) are key cytokines 
in an inflammatory response, and transforming growth factor 1 (TGF- 1) promotes 
hepatic fibrogenesis.  The association of polymorphisms in the genes for these cytokines 
with liver fibrosis is controversial.  The aim of this study was to examine the possible 
association of IL-1 , IL-1RN and TGF- 1 polymorphisms with the progression of liver 
fibrosis in the Japanese population using cross-sectional and longitudinal study designs. 
We examined 183 patients with hepatitis C virus (HCV)-related chronic liver disease (93 
chronic hepatitis and 90 with cirrhosis).  Some of the chronic hepatitis cases were divid-
ed into progressive fibrosis and non-progressive fibrosis.  IL-1  –31T/C, IL-1RN variable 
number of tandem repeats (VNTR) and TGF- 1 +869 T/C polymorphisms were ana-
lyzed using a polymerase-chain reaction-based assay.  In the cross-sectional study, there 
were no significant differences in the genotype distributions of IL-1 , IL-1RN and TGF-
1 between chronic hepatitis and liver cirrhosis.  No significant differences were found 
among Child-Pugh grades in cirrhosis patients.  In the longitudinal study, there were no 
significant differences in the genotype distributions of IL-1 , IL-1RN and TGF- 1 be-
tween progressive fibrosis and non-progressive fibrosis.   No significant differences in the 
speed at which liver fibrosis develop were found among the genotypes of IL-1 , IL-1RN 
and TGF- 1.  In disagreement with other studies, the functional gene polymorphisms of 
IL-1 , IL-1RN and TGF- 1 were not associated with the progression of liver fibrosis in 
Japanese patients with HCV-related chronic liver disease.
Key words:  interleukin-1 ; interleukin-1 receptor antagonist; liver fibrosis; polymorphism; 
transforming growth factor- 1 
 In hepatitis C virus (HCV)-related chronic liver 
disease, the progression of liver fibrosis is a com-
mon problem, and the rate of progression varies 
markedly between patients (Marcellin et al., 2002; 
McCaughan and George, 2004; Feld and Liang, 
2006; Massard et al., 2006).  Some patients with 
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chronic hepatitis C rapidly develop significant 
fibrosis and cirrhosis, while others remain asymp-
tomatic without progression.  In general, an older 
age at infection, excessive alcohol consumption, 
male gender, overweight and immunodeficiency 
are known to have an association with a more 
rapid progression of fibrosis in chronic hepatitis C. 
In addition, evidence indicates that genetic factors 
influence the natural course of chronic hepatitis 
C.  Since fibrosis of the liver is a highly dynamic 
process, a number of polymorphisms in functional 
genes as host genetic factors influence its progres-
sion in patients with chronic hepatitis C, contrib-
uting to inter-individual variability (Bataller et al., 
2003).  Among these polymorphisms, especially 
the proinflammatory or profibrogenetic cytokine 
gene polymorphisms are considered to strongly 
influence the progression of fibrosis (Bataller et 
al., 2003).  Indeed, the capacity to produce cyto-
kines in individuals largely depends on genetic 
polymorphisms.  Several studies have examined 
the possible association of gene polymorphisms 
of proinflammatory cytokines, interleukin-1
(IL-1 ) and interleukin-1 receptor antagonist (IL-
1RN), and profibrogenetic cytokine, transforming 
growth factor- 1 (TGF- 1), with the progression 
of liver fibrosis in chronic hepatitis C (Powell et 
al., 2000; Gewaltig et al., 2002; Bahr et al., 2003; 
Suzuki et al., 2003; Tanaka et al., 2003; Wang et 
al., 2005), but these results are controversial.  In 
this study, we investigated cross-sectionally and 
longitudinally the association of functional poly-
morphisms in the genes for these cytokines with 
the progression of liver fibrosis in Japanese pa-
tients with HCV-related chronic liver disease. 
 
Materials and Methods
 
Subjects
 
One hundred and eighty-three patients with HCV-
related chronic liver disease were enrolled in this 
study (Table 1).  All the patients were Japanese 
and positive for HCV-RNA.  The diagnosis of liv-
er disease was confirmed by laboratory tests and/
or histological examination.  All patients were 
negative for hepatitis B surface antigen and hu-
man immunodeficiency virus antibody.  The sub-
jects of this study were 93 patients with chronic 
hepatitis (mean age 63.6 ± 10.8 years, 53 men and 
40 women) and 90 patients with liver cirrhosis 
(mean age 66.4 ± 9.4 years, 45 men and 45 wom-
en). Among the chronic hepatitis patients, we have 
selected 43 who were followed up for 5 years, and 
divided them into the progressive fibrosis group 
(n = 26, 13 men and 13 women, mean age 55 ± 9 
years) and a non-progressive fibrosis group (n = 
17, 9 men and 8 women, mean age 63 ± 10 years) 
according to the 5-year change in the FibroIndex 
(Koda et al., 2007) which was determined based 
on the platelet count, L-asparate aminotransferase 
(AST) level and -globulin level, as an index for 
assessing fibrotic stage at both one point and fol-
low up: 1.738 – 0.064 (platelets × 104 /mm3) + 
0.005 (AST IU/L) + 0.463 ( -globulin g/dL).  This 
Table 1.  Characteristics of patients
 Whole patients Patients with Patients with  
 [183]  chronic hepatitis [93]  liver cirrhosis [90]
Age  (year)   64.9 ± 10.2   63.6 ±  10.8 66.4 ± 9.4
Gender  (male/female) 98/85 53/40 45/45
AST  (IU/mL)   68.7 ±  41.8   57.0 ±  38.3   81.4 ±  42.3
ALT  (IU/mL)   68.9 ±  52.6   68.8 ±  60.4   69.2 ±  42.4
Platlet  (× 104/mL)   14.8 ±  14.7   18.6 ±  17.1   10.7 ±  10.0
HCV RNA  (kIU/mL) 359  ±  294 462 ±  309 217 ±  193
ALT, L-alanine aminotransferase; AST, L-asparate aminotransferase; HCV, hepatitis C virus.
[  ], number of patients.
91
Cytokine genotypes and liver fibrosis 
study was approved by the Committee for the Eth-
ics of Medical Experiments on Human Subjects 
of the Medical Faculty of the Tottori University, 
and written-informed consent was obtained from 
each subject before blood was collected. 
 In addition, the rate at which fibrosis pro-
gressed was examined in some chronic hepatitis 
patients identified at the exact same time point of 
HCV-infection by careful anamnesis.  The rate of 
progression per year was estimated as the fibrosis 
stage (score 0 to 4) by New Inuyama classification 
(Ichida et al., 1996) at the time of biopsy divided 
by the duration of infection with HCV or as the 
difference in the fibrosis stage between the first 
and second biopsy divided by the time interval 
between the 2 biopsies. 
 
DNA extraction
 
Genomic DNA was extracted from peripheral 
white blood cells using a DNA extracting kit (DNA 
Quick II: Dainippon Pharmaceutical, Osaka, 
Japan) according to the manufacturer’s instruc-
tions. 
 
Analysis of the IL-1  –31T/C genotype
 
The IL-1  –31T/C genotype was analyzed us-
ing the PCR with mutagic primers, followed by 
the restriction fragment length polymorphism 
(RFLP) method according to Wang et al. (2003). 
The PCR was carried out in a final volume of 
25 μL:  2 μL (50 ng) of genomic DNA, 10 pmol 
of forward primer (5'-AGAAGCTTCCACCAA 
TACTC-3'), 10 pmol of reverse primer (5'-AGC 
ACCTAGTTGTAAGGAAG-3'), 200 μM of each 
nucleotide, 1.5 mM MgCl2, 1 unit of Taq DNA 
polymerase (Takara Shuzo, Kusatsu, Japan), and 
18 μL of sterile H2O.  The conditions for amplifi-
cation were as follows:  initial denaturation at 95˚
C for 1 min, followed by 36 cycles of denaturation 
at 94˚C for 45 s, annealing at 54˚C for 50 s, and 
extension at 72˚C for 1 min.  RFLP for IL-1  was 
carried out.  In brief, a mixture of 5 μL of PCR 
product, 2 μL of 10× NE buffer (300 mM NaCl, 
10 mM Tris-HCl, 0.1 mM EDTA, 1 mM DTT, 
500 ng/mL bovine serum albumin and 50% glyc-
erol, pH 7.4), 1 μL of Alu I (10 units/µL) (Takara 
Shuzo) and 12 μL of sterile H2O was incubated 
at 37˚C overnight. The mixture was loaded onto 
a polyacrylamide gel (total concentration 10%, 
concentration of cross-linker 3%, 1× TBE buffer: 
89 mM Tris, 89 mM borate and 2.2 mM EDTA). 
Electrophoresis was performed at 200V for 70 
min at 20˚C using 1× TBE buffer.  Bands were 
visualized by silver staining (Fig. 1a). 
 
Analysis of the IL-1RN VNTR genotype
 
The IL-1RN variable number of tandem repeats 
(VNTR) genotype was analyzed by amplification 
followed by staining of the PCR products directly 
according to Wang et al. (2003).  The PCR was 
carried out in a final volume of 25 μL:  2 μL (50 
ng) of genomic DNA, 0.2 μL of forward primer 
(5'-CCCCTCAGCAACACTCC-3'), 0.2 μL of re-
verse primer (5'-GGTCAGAAGGGCAGAGA-3'), 
2.0 μL of each nucleotide, 2.5 μL of MgCl2, 1 
unit of Taq DNA polymerase (Takara Shuzo), and 
18 μL of sterile H2O.  The conditions for ampli-
fication were:  initial denaturation at 95˚C for 10 
min, followed by 5 cycles of denaturation at 94˚C 
for 45 s, annealing at 65˚C for 30 s, and extension 
at 72˚C for 30 s, then 30 cycles of denaturation at 
94˚C for 30 s, annealing at 60˚C for 30 s, exten-
sion at 72˚C for 30 s, and finally 5 cycles of dena-
turation at 94˚C for 30 s, annealing at 55˚C for 30 s, 
and extension at 72˚C for 30 s.  The PCR products 
were loaded directly onto a polyacrylamide gel 
(total concentration 10%, concentration of cross-
linker 3%, 1× TBE buffer:  89 mM Tris, 89 mM 
borate and 2.2 mM EDTA).  Electrophoresis was 
performed at 200 V for 120 min at 20˚C using 
1× TBE buffer.  Bands were visualized by silver 
staining.  Five alleles were assigned based on am-
plicon size:  allele 1 (4 repeats) 442 bp, allele 2 (2 
repeats) 272 bp, allele 3 (3 repeats) 357 bp, allele 
4 (5 repeats) 532 bp and allele 5 (6 repeats) 627 
bp (Fig. 1b).
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Analysis of the TGF- 1 +869 T/C genotype
 
The TGF- 1 genotype was analyzed by PCR fol-
lowed by RFLP according to Wood et al. (2000). 
The PCR was carried out in a final volume of 
40 μL:  3 μL of genomic DNA, 0.32 μL of for-
ward primer 5'-TTCCCTCGAGGCCCTCCTA-3', 
0.32 μL of reverse primer 5'-GCCGCAGCTT-
GGACAGGATC-3', 2.4 μL of each nucleotide, 
4.0 μL of 25 mM MgCl2, 0.8 units of Taq DNA 
polymerase (Takara Shuzo) and 29.8 μL of ster-
ile H2O.  The conditions for amplification were: 
initial denaturation at 96˚C for 10 min, followed 
by 30 cycles of denaturation at 96˚C for 60 s, an-
nealing at 62˚C for 60 s, extension at 73˚C for 60 s 
and 73˚C for 5 min.  The RFLP analysis for TGF-
1 was carried out with a mixture of 10 μL of the 
PCR product, 2.0 μL of 10× NE buffer (50 mM 
NaCl, 10 mM Tris-HCl, 10 mM MgCl2 and 1 mM 
dithiothreitol, pH 7.9), 0.2 μL of bovine serum al-
bumin, 0.25 μL of MspA1-I (20 units/mL) (Takara 
Shuzo) and 7.55 μL of sterile H2O.  The solution 
was incubated at 37˚C overnight.  The mixtures 
were loaded onto a polyacrylamide gel (total con-
centration 15%, concentration of cross linker 3%, 
1× TBE buffer:  89 mM Tris, 89 mM borate and 
2.2 mM EDTA).  Electrophoresis was performed 
at 200 V for 150 min at 10˚C using 1× TBE buffer 
as a tank buffer. Bands were visualized with silver 
staining (Fig. 1c).
 
Plasma IL-1  concentration 
 
The plasma concentration of IL-1  was measured 
with an ELISA kit (BioSource Europe S.A., 
Nivelles, Belgium). 
 
Statistical analyses
 
Values were expressed as the mean ± SD.  Differ-
ences in genotype distributions were tested with 
the 2 test.  The differences of data between the 
2 groups were assessed with a t test. A P value of 
< 0.05 was regarded as statistically significant.   
 
Results
 
Genotype distributions and allelic frequen-
cies of IL-1  –31 T/C, IL-1RN VNTR and TGF-
1 +869 T/C 
 
Genotype distributions and allelic frequencies of 
IL-1  –31, IL-1RN and TGF- 1 +869 are shown 
in Table 2.  The frequency of each genotype was 
Fig. 1.  Analysis for gene polymorphisms of IL-1 , IL-1RN and TGF- 1.  a:  IL-1  –31 T/C genotypes.  b:  IL-1RN 
VNTR genotypes.  c:  TGF- 1 +869 T/C genotypes.  IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor antagonist; 
TGF- 1, transforming growth factor- 1.
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in the Hardy-Weinberg equilibrium ( 2 = 1.597, 
P = 0.450 for IL-1 ; 2 = 0.035, P = 0.983 for IL-
1RN; 2 = 0.938, P = 0.626 for TGF- 1).  No 
significant differences in genotype distribution or 
allelic frequency were observed between chronic 
hepatitis and liver cirrhosis, although the TGF- 1 
+869 C/C homozygote with higher transcriptional 
activity tended to more often be in the chronic 
hepatitis group.  When the cases of cirrhosis were 
divided into grade A and grade B + C accord-
ing to the Child-Pugh classification (Pugh et al., 
1973), there was no significant difference in geno-
type frequencies between the 2 groups grade A 
and grade B + C groups at each gene (Table 3), al-
though the TGF- 1 +869 C/C homozygote tended 
to be high in grade A cirrhosis but not significant 
(P = 0.067).
Difference in genotype frequency of IL-1 , 
IL-1RN and TGF- 1 between progressive 
and non-progressive fibrosis 
 
The chronic hepatitis patients were divided into 
those with progressive fibrosis and those with 
non-progressive fibrosis according to the 5-year 
change of FibroIndex (Table 4).  No significant 
differences in genotype frequency were observed 
between the 2 groups.  In addition, the 5-year 
Table 2.  Genotype distributions and allelic frequencies in patients with HCV-related chronic liver 
disease
 Genotype distribution Allele frequency
IL-1  –31T/C  T/T  T/C  C/C P value T C P value
  Chronic hepatitis  [92] 27%  49%  24% 0.539 0.51 0.49 0.488
  Liver cirrhosis  [85] 23%  46%  31%  0.46 0.54
IL-1RN VNTR   1/1  1/2 1/4 2/4 1/3 P value Allele 2 Others P value
  Chronic hepatitis  [92] 86% 11% 1% 1% 1% 0.824 0.06 0.94 0.999
  Liver cirrhosis  [91] 87% 10% 2% 1% 0%  0.11 0.89
TGF- 1 +869T/C  T/T  T/C  C/C P value T C P value
  Chronic hepatitis [91] 29%  43%  28% 0.211 0.51 0.49 0.228
  Liver cirrhosis  [90] 35%  47%  18%    0.59 0.41
For technical reasons, genotyping was not possible in all patients.
HCV, hepatitis C virus; IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor antagonist; TGF- 1, transforming growth factor- 
1; VNTR, variable number of tandem repeats. 
[  ], number of patients. 
Table 3.  Genotype distributions and the Child-
Pugh classification in patients with liver cirrhosis
  Child-Pugh
   Genotype A B + C P value
IL-1  –31 T/C
 T homozygote 33 (79%) 24 (71%) 0.424
 C carrier   9 (21%) 10 (29%) 
IL-1RN VNTR
 Allele 2   5 (11%)   4 (11%) 0.999
 Others 40 (89%) 32 (89%)
TGF- 1 +869T/C
 T carrier 33 (77%) 34 (92%) 0.067
 C homozygote 10 (23%)   3 ( 8%) 
IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor an-
tagonist; LC, liver cirrhosis; TGF- 1, transforming growth 
factor- 1. 
changes of FibroIndex did not differ between the 
genotypes in the progressive or non-progressive 
group. 
 
Speed at which liver fibrosis developed ac-
cording to genotypes for IL-1 , IL1-RN and 
TGF- 1
 
Among the chronic hepatitis patients in whom 
the rate at which liver fibrosis developed was 
estimated by careful anamnesis, comparisons 
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were made according to genotype (Table 5).  No 
significant differences in clinical findings such 
as age, gender, infection duration, and laboratory 
data were observed (Table 1).  Although the C/C 
homozygote of TGF- 1 tends to develop fibrosis 
at a slower speed than the T carrier, there were no 
significant differences in terms of each gene. 
 
Speed of liver fibrosis estimated by follow 
up liver biopsies among genotypes of IL-1 , 
IL1-RN and TGF- 1
 
Among chronic hepatitis patients in whom the 
rate at which liver fibrosis developed was estimat-
Table 5.  The speed at which liver fibrosis devel-
oped estimated by careful anamnasis among 
genotypes
 Liver fibrosis speed
 (stage/infec-
 tion duration) P
                         Genotype (mean ± SEM) value 
IL-1   T homozygote [ 6] 0.117 ± 0.038 0.560
–31T/C C carrier [16] 0.167 ± 0.050
IL-1RN Allele 2  [ 1] 0.108 ± 0.000 0.772
VNTR Others   [23] 0.159 ± 0.036 
TGF- 1 T carrier  [21] 0.162 ± 0.040 0.534
+869 T/C C homozygote [ 3] 0.094 ± 0.007
IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor antago-
nist; TGF- 1, transforming growth factor- 1; VNTR, vari-
able number of tandem repeats.
[  ], number of patients.
Table 6.  The speed at which liver fibrosis de-
veloped estimated by follow-up liver biopsies 
among genotypes
 Liver fibrosis speed
 (stage/infec-
 tion duration) P
                         Genotype (mean ± SEM) value 
IL-1   T homozygote [ 4] 0.046 ± 0.030 0.811
–31T/C C carrier [ 8] 0.091 ± 0.126
IL-1RN Allele 2  [ 2] –0.240 ± 0.023 0.858
VNTR Others   [11] 0.027 ± 0.113 
TGF- 1 T carrier  [ 6] 0.121 ± 0.169 0.613
+869 T/C C homozygote [ 6] 0.032 ± 0.028
IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor antago-
nist; TGF- 1, transforming growth factor- 1; VNTR, vari-
able number of tandem repeats.
[  ], number of patients.
ed with the follow-up liver biopsies, the speed of 
the disease’s progression was examined according 
to genotypes (Table 6).  There were no statistical-
ly significant differences between the genotypes, 
although the TGF- 1 C/C homozygote tended to 
have a slower progression than the T carrier.
 
Plasma IL-1  concentration according to 
genotype of IL-1  and IL-1RN
 
We examined the relationship of plasma IL-1
concentration with the genotypes of IL-1  and IL-
1RN, and found no significant differences in the 
IL-1  concentrations between IL-1  –31C carrier 
Table 4.  Genotype frequency in the progressive and non-progressive fibrosis groups 
 Non-progressive group Progressive group
 FibroIndex  Genotype FibroIndex  Genotype 
                      Genotype (Δ)  frequency (Δ)  frequency P value  
IL-1  T homozygote –0.311 ± 0.266 6 (24%) 0.433 ± 0.504  3 (17%) 0.832
–31T/C C carrier –0.235 ± 0.146 16 (76%) 0.392 ± 0.424 15 (83%)
IL-1RN  Allele 2 –0.153 ± 0.159 3 (11%) 0.344 ± 0.279  2 (11%) 0.999
VNTR Others –0.284 ± 0.197 24 (89%) 0.407 ± 0.444 16 (89%)
TGF- 1 T carrier –0.234 ± 0.192 18 (67%) 0.427 ± 0.502 12 (71%) 0.999
+869T/C C homozygote –0.284 ± 0.197  9 (33%) 0.407 ±  0.444  5 (29%)
Δ, increment variable; IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor antagonist; TGF- 1, transforming growth factor- 1; 
VNTR, variable number of tandem repeats.
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and T homozygote, and between IL-1RN allele 2 
and the others (Table 7). 
 
 
Discussion
 
In the present cross-sectional and longitudinal 
studies, we found no close association of function-
al gene polymorphisms of IL-1  –31T/C, IL-1RN 
VNTR and TGF- 1 +869T/C with the progression 
of liver fibrosis in Japanese patients with HCV-
related chronic liver disease, although the TGF- 1 
C/C homozygote tended to have a slower progres-
sion of liver fibrosis.
 IL-1  is a key cytokine in the inflammatory 
response and its biological activities promotes var-
ious diseases including chronic hepatitis, in which 
an increase in IL-1  stimulates the progression 
of liver fibrosis.  In fact, serum levels and hepatic 
mRNA levels of IL-1  are reported to be elevated 
in patients with chronic hepatitis C (Tilg et al., 
1992; Gramantieri et al., 1999).  The IL-1 gene 
family at 2q13-14 encodes 3 proteins.  In this gene, 
some polymorphisms have seen reported: one is 
in the promoter region at position –511 and –31, 
representing C  T and T  C transitions, which 
are in near total linkage disequilibrium (El-Omar 
et al., 2000).  The IL-1  –31 C allele (–511 T) 
has higher transcriptional activity than the IL-1  
–31 T allele (–511 C) (Bataller et al., 2003) sug-
gesting that –31C allele carriers may overproduce 
the IL-1  protein, resulting in a more aggressive 
necroinflammation and in a rapid progression of 
liver fibrosis. 
 Takamatsu et al. (2000) have reported that 
the carriers of the –511 allele 2 (–31C) were sig-
nificantly more common in Japanese patients with 
alcoholic cirrhosis than in those with noncirrhotic 
alcoholic liver disease.  By contrast, Bahr et al. 
(2003) have reported that IL-1  –511T/C genotype 
distribution was similar between HCV-induced 
chronic hepatitis and cirrhosis in the German pop-
ulation.  Tanaka et al. (2003) have also reported 
that IL-1  –511C/T genotype distributions did not 
differ between F0-F2 and F3-F4 in HCV-related 
chronic liver disease in the Japanese population. 
In our study, we found no significant difference of 
IL-1  –31T/C genotype frequency between HCV-
related chronic hepatitis and cirrhosis in Japanese. 
Taken together, the IL-1  –31T/C genotype does 
not influence the rate of progression of liver fi-
brosis in patients with HCV-related chronic liver 
disease. In fact, we found no significant difference 
in the plasma IL-1  concentration in patients with 
HCV-related chronic liver disease according to 
IL-1  –31T/C genotypes or IL-1RN VNTR geno-
types.
 IL-1 RN, an anti-inflammatory molecule 
which competes for binding with the IL-1 recep-
tor, is encoded by the IL-1RN gene (Santtila et 
al., 1998).  This gene has a penta-allelic 86-bp 
tandem repeat polymorphisms VNTR in intron 2. 
IL-1RN allele 2 has been shown to be associated 
with enhanced IL-1  production in vitro (Sant-
tila et al., 1998) and in vivo (Hwang et al., 2002). 
Bahr et al. (2003) have reported that IL-1RN 
allele 2 is significantly more prevalent in HCV-
related cirrhosis as compared with HCV-related 
chronic hepatitis.  In the Japanese population, 
Tanaka et al. (2003) have reported that IL1RN 
VNTR genotype distributions did not differ be-
tween F0–F2 and F3–F4 in HCV-related chronic 
liver disease.  In our study, we also found no sig-
nificant difference of IL-1RN VNTR genotype 
between HCV-related chronic hepatitis and cir-
rhosis in Japanese.  As the reason for the differ-
Table 7.  Plasma IL-1  concentration according 
to genotype
 Plasma IL-1
 (ng/mL)
                 Genotype (mean ± SD)  P value
Il-1  –31T/C T homo 12.4 ± 14.2 0.757
 C carrier 13.5 ± 13.7
IL-1RN VNTR Allele 2 12.6 ± 4.4 0.753
 Others         14.0 ± 14.1
IL-1 , interleukin-1 ; IL-1RN, interleukin-1 receptor antago-
nist; TGF- 1, transforming growth factor- 1; VNTR, vari-
able number of tandem repeats.
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ence between Caucasian and Japanese, the allelic 
frequency itself has been attributed to be different 
between the both populations.  In fact, allele 2/2 
of IL-1RN was observed in 10 to 30% of the Cau-
casian control population (Bahr et al., 2003), but 
only 0 to 2% of the Japanese control population 
(Tanaka et al., 2003; Wang et al., 2003).   
 TGF- 1 is a pluripotent cytokine that pro-
motes hepatic fibrogenesis by stimulating the 
synthesis of extracellular matrix (ECM), inhibit-
ing the degradation of ECM, and activation of 
hepatic stellate cells.  Indeed, the plasma TGF- 1 
concentration is increased in patients with chronic 
hepatitis, and correlated with the degree of liver 
fibrosis (Murawaki et al., 1998; Thushima et al., 
1999).  In the human TGF- 1 gene, which is lo-
cated at chromosome 19q13, eight polymorphisms 
are presently known including –800G/A, –509C/T, 
+869T/C and +915G/C (Gewaltig et al., 2002). 
The +869T homozygote, the +915G homozygote 
and the –509T carrier are reported to have higher 
levels of TGF- 1 (Grainger et al., 1999).
 There are several studies about the associa-
tion of TGF- 1 gene polymorphisms with the 
progression of liver fibrosis in patients with HCV-
related chronic liver disease, but the results are 
controversial.  Powell et al. (2000) have shown 
that the TGF- 1 +915G/G homozygote with high 
transcriptional activity was more often in stage 
III/IV in Australian HCV-related chronic liver 
disease patients, whereas TGF- 1 –509C/T and 
+869T/C did not differ among the stages of fibro-
sis.  In contrast with Powell’s data, Wang et al. 
(2003) have shown that the TGF- 1 +869 T car-
rier and +915 G/C heterozygote are more often 
in stage III/IV in German HCV patients.  Suzuki 
et al. (2003) have shown no association of TGF-
1 +869T/C polymorphism with the progression 
of liver fibrosis in Japanese HCV patients.  Since 
the TGF- 1 +915 G/C polymorphism was not 
observed in Japanese (Suzuki et al., 2003), we 
analyzed only the TGF- 1 +869T/C genotype in 
this study.  In agreement with Suzuki’s results, 
we found no significant association of TGF- 1 
+869T/C with the progression of liver fibrosis in 
HCV-related chronic liver disease.
 Gewaltig et al. (2002) examined the associa-
tion of TGF- 1 polymorphisms with the rate at 
which fibrosis developed in 26 patients who un-
derwent repeatable liver biopsy, and showed that 
the presence of proline at codon 10 and/or 25 was 
associated with a faster progression of fibrosis: 
+869 C carriers and +915G/C heterozygote devel-
oped fibrosis faster.  By contrast, our longitudinal 
study, in which disease progression was estimated 
based on the duration of HCV infection or the 
change of stage in follow-up biopsies, has shown 
that the TGF- 1 +869 C/C homozygote had a 
slower rate of progression than T carriers, but the 
difference was not significant.  We can not pres-
ently explain this difference, but race, the evalua-
tion system, and patient background may all have 
had an effect.  Large-scale, well-designed studies 
are required to clarify this issue. 
 In conclusion, we did not find a close asso-
ciation of IL-1 , IL-1RN and TGF- 1 genotype 
distributions with the progression of liver fibrosis 
in HCV-related chronic liver disease in cross-
sectional and longitudinal studies.
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